Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Total Current Liabilities (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Total Current Liabilities for 6 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities fell 17.74% to $2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.3 million, a 17.74% decrease, with the full-year FY2024 number at $2.2 million, down 33.78% from a year prior.
  • Total Current Liabilities was $2.3 million for Q3 2025 at Ensysce Biosciences, down from $2.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $16.5 million in Q4 2021 to a low of $319180.0 in Q1 2021.
  • A 5-year average of $4.9 million and a median of $2.8 million in 2024 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: plummeted 90.87% in 2021, then surged 2657.66% in 2022.
  • Ensysce Biosciences' Total Current Liabilities stood at $16.5 million in 2021, then tumbled by 42.58% to $9.5 million in 2022, then crashed by 64.78% to $3.3 million in 2023, then tumbled by 33.78% to $2.2 million in 2024, then increased by 4.42% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Total Current Liabilities are $2.3 million (Q3 2025), $2.5 million (Q2 2025), and $1.8 million (Q1 2025).